Responsive Image

The Personalised Medicine Dynamization Platform (DNA.MedPer) forms part of one of the lines of work of the Department of Economic Development to promote the personalised medicine sector in Navarre, considered a priority area within the S4 Intelligent Development Strategy promoted by the Government of Navarre. 

The creation of this specific platform for Personalised Medicine is directed at setting up a space for the transfer of knowledge from the field of investigation to business, in order to strengthen competitiveness and generate value in the business and healthcare sectors in Navarra. 

Responsive Image

Genomics and Personalised Medicine 

 
 
Responsive Image

Biopharma 

 
 
Responsive Image

Medical devices 

 
 
Responsive Image

Prevention and wellness  

 
 

The Department of Economic Development brings together more than 40 professionals from the personalised medicine sector for the purpose of creating synergies and new business models  

Responsive Image

On 22nd November, 2021, Uxue Itoiz, the Director General of Industry, Energy and the S3 Strategic Projects, took part in the first dynamization of the personalised medicine working groups. More than 40 professionals attended the event, coming from the university community, private companies and technology centres, seeking to create synergies for the development of technologies and business models. This is the first session of this programme which will continue to be implemented online through the virtual platform created for this purpose.  

Itoiz pointed out that personalised medicine is part of the S3 Smart Specialisation Strategy given that "it is a vector for economic development in our community and will also improve the quality of life of all the citizens of Navarra". Furthermore, Itoiz emphasised that "the working groups will make it possible to develop business opportunities and to ensure that investigation is transferred to entrepreneurial projects".  
  
During the event, the preliminary results of the surveys conducted among participants were presented, showing that two of the key objectives of the members were to seek ways to exploit genomic data in order to develop new technologies and to transfer knowledge as a source of business opportunities.  

Second dynamization of the Personalised Medicine working groups 

Responsive Image

The Second Personalised Medicine Dynamization Event was held on 21st March 2022, with high participation from the more than thirty companies and entities forming part of the personalised medicine working groups of Navarra: Genomics and Personalised Medicine, Medical Devices, Biopharma, and Prevention and Wellness.  

In turn, the event was also in response to an invitation from the "Forum, I invite you to get to know my company, entity, etc.". The company Vidorreta Design hosted the dynamization event, during which it introduced us to the new company in its group, Ysium Medical, specialising in medical devices.  


This was followed by a round of speakers from four companies, with the collaboration of Olga Romero from  CEIN (European Business Innovation Centre of Navarra), during which they described their areas of work and latest achievements. The speakers from the companies were: Mariano Oto  (NUCAPS Nanotechnology), Maite Agueros Bazo (InnoUp Farma), Javier Campión Zabalza (Making Genetics) y Jesús Pérez (Tedcas).  Las empresas recibieron sugerencias y numerosas preguntas por parte de los asistentes: Maria José Calasanz, Antonio Pineda, Elias Toral, Juan Manuel Saiz (Cima), Iñigo Lasa (Navarrabiomed), Dámaso Molero (3P Biofarmaceuticals), Tomás Belzunegui (UPNA), César Gonzalvo (Iruña Tecnología de Automatización), Yaki Hernández (SARAY Asociación Cáncer Mama), Marta Díez (Tedcas) and Cecilia Galbete (Nutrición 3G). 

This round was followed by a presentation of the indicators of the "Personalised Medicine Dynamization in Navarra" website and the "work platform of the dynamization groups", as well as the latest advances in these sections. The focus was also on the new calls for proposals that will soon be published for research and development in Personalised Medicine.